Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Thanks Chester, I was sat here wondering about the significance of the mention of “follow up data from the BioNTech mRNA vaccine”
Surely has to be Scancell relevant, for them to have included that line.
You mean this?
https://www.abstractsonline.com/pp8/#!/20272/presentation/11402
(You may need to copy paste)
As we know from RNS, Scancell have recently attended Oxford Biologics in London. Worth pointing out I think that there is a sister conference in October, in San Diego and I suspect that might also be a Scancell road trip. Perhaps not in a limousine though 😂
https://oxfordglobal.com/biologics/events/biologics-us-2024
HAGW (Q1 comes to an end one week tomorrow - a recruitment and data published milestone)
Attempting to make comparisons in that way is in my opinion, utterly pointless. There are way, way too many variables.
We know the timeline here to expect data (assuming no delays) and it is that, that will ultimately drive any blue chip pharma interest / deal.
A reminder of the PRESENTATION later today.
https://oxfordglobal.com/biologics/events/biologics-2024#speakers
The Agenda is available for download at the link. Best of luck to the Scancell scientists.
Next stop Barcelona.
HAGW
Green453 - the Scancell lab folk look a bit like this, except they’re not making steam irons.
https://www.youtube.com/watch?v=2r7XfhTKRMw
Violin - I don’t think anyone should be using the FARN product BEXMAB as a “potential blueprint” for SCIB. For a start, FARN have only recently had their pants pulled down due to the need to disclose events of default on debt obligations to their lender. Saying that Scancell are better funded is somewhat of an understatement and will clearly have an impact on development & commercialisation.
So personally, I don’t see any correlation and really hope none exists.